Sydney, May 18, 2026, 08:01 AEST
- ALS closed Friday at A$22.20, down 0.31%, before Monday’s FY26 results and final dividend update.
- The stock slipped about 0.6% last week, less than the S&P/ASX 200’s roughly 1.3% fall.
- Investors are watching for any cost, data or revenue hit from the company’s May cyber incident.
ALS Ltd heads into Monday’s results day with its shares little changed for the week, but with investors looking for sharper detail on a cyber incident, margins and the final dividend.
The timing matters. ALS has scheduled its FY26 results release and final dividend announcement for May 18, with a results briefing listed for 10 a.m. AEST. At the time of the dateline, ASX cash-market trading was still in pre-open; normal trading begins around 09:59:45 Sydney time and runs until 16:00.
Monday is not listed as an ASX market holiday. The exchange’s 2026 trading calendar shows the next scheduled full closure is King’s Birthday on June 8.
ALS last traded at A$22.20 on Friday, down 0.31%, after moving between A$22.05 and A$22.82. The stock’s close was about 0.6% below its May 8 finish of A$22.33. Australia’s S&P/ASX 200, the local benchmark index, ended Friday at 8,630.80, down 0.11%, leaving it about 1.3% lower for the week.
The result will test whether ALS carried first-half momentum into March. In November, the company reported H1 FY26 underlying revenue of A$1.66 billion, up 13.3%, and underlying EBIT — adjusted earnings before interest and tax — of A$287.2 million, up 14.7%. Underlying NPAT, an adjusted net profit measure that strips out unusual or non-recurring items, rose 17.2% to A$178.4 million.
At that half-year result, ALS Chairman Nigel Garrard said the group had delivered “resilient margins”. CEO Malcolm Deane said the first half was “driven by strength in Commodities”, while Life Sciences faced “lower growth conditions”. That split is likely to matter again on Monday. ASX Announcements
The cyber update is the fresher overhang. ALS said on May 5 that unauthorised third-party access to some IT systems caused temporary disruption to parts of the group’s operations. The company said the vast majority of operations had been restored, but targeted remediation was continuing and it was still investigating potential data impacts.
Reuters reported that ALS, whose testing work spans commodities, food and pharmaceuticals, had notified the Australian Cyber Security Centre and was working with clients, authorities and regulators. The company did not give a timeline or details on when the disruption began.
The competitive read is broader than one stock. ALS sits in a global testing and inspection market alongside SGS, Bureau Veritas and Intertek, where scale and lab networks matter. Reuters reported last year that Bureau Veritas and SGS had discussed a deal to create a testing and certification group worth more than $30 billion, a reminder of the pressure for size in the sector.
Analyst data compiled by Investing.com showed an average 12-month price target of A$23.92 for ALS across 14 analysts, with estimates ranging from A$16.70 to A$28. Nine rated the stock a buy, three a hold and two a sell, showing support but not a one-way view.
But the risks are plain. A bigger-than-expected cyber cost, evidence of data compromise, weaker Life Sciences growth, slower mineral sample volumes or a lower final dividend could all change the tone quickly. There is also the old reporting-day problem: adjusted profit may look firm while cash flow, statutory profit or guidance does not do enough.
Monday’s briefing should set the tone for the week. After the results, the next dated items for shareholders are the final dividend record date on June 15, the dividend reinvestment plan election date on June 16, payment on July 3 and the annual meeting on July 28.
